DiagnaMed Holdings (CSE: DMED) is moving to enhance its brain health artificial intelligence platform known as CERVAI. The company has entered into a licensing agreement with the University of Miami to add additional features to the current offering.
The licensing agreement will see the integration of a novel brain health platform that has been designed for the evaluation, diagnosis and monitoring of brain health into that of CERVAI. The tech was developed by James Gavin, whom is Professor of Neurology and Psychiatry and Behavioral Sciences at the Miller School of Medicine at the University of Miami, and also the founding director of the Comprehensive Center for Brain Health at the U of M Health System.
READ: DiagnaMed Focuses On Brain Health AI Platform Development
Sponsored · Altamira Gold Corp.
The platform itself is said to feature novel brain function assessments, as well as tools to evaluate overall brain health. Such tools can examine cognitive performance, ADRD risk factors, and determine if there is evidence of risk of further decline or future impairment. These data points are said to be validated against normal and impaired cognitive function based on clinical gold standards.
Furthermore, after analyzing these data points, the platform outputs an overall patient risk score that can be used to implement a treatment regime. Integrated with the CERVAI platform, it is expected that it will have the ability to delay or prevent the onset of cognitive decline and improve quality of life for patients and caregivers.
READ: DiagnaMed Looks To Obtain Approval For Brain Age Clinical Tool In Q4
“We continue to strengthen the potential of CERVAI™, our proprietary Brain Health AI Platform leveraging Generative AI, by integrating a clinically validated novel brain health solution from the University of Miami, which will allow us to evaluate overall brain health and provide actionable data to implement personalized interventions for cognitive decline for the millions of people suffering from mental health and neurodegenerative diseases,” commented Chairman Fabio Chianelli.
DiagnaMed Holdings last traded at $0.08 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
